• Pancreatic cancer: standard combination therapy best for recurrence

    Median OS was 14 vs 8 months with non-standard combinations.

  • Resected PDAC: study identifies optimal cutoff for early vs late recurrence

    Later recurrence is associated with better prognosis.

  • Pancreatic cancer: weight loss has negative effect on ACT continuity

    Findings underscore the importance of nutritional intervention for optimal outcomes.

  • Neuroendocrine tumors: combination therapy often offers best results

    Review parses data from 30 randomized controlled trials.

  • UK GPs lack tools necessary for early diagnosis of pancreatic cancer
    UK GPs lack tools necessary for early diagnosis of pancreatic cancer

    Findings from a new survey for Pancreatic Cancer UK.

  • Pancreatic cancer: computer model decodes optimal treatment strategy

    Predictions confirmed in a clinical cohort.

  • Pancreatic cancer: intraoperative ultrasound improves resectability determination

    IMAGE shows value over CT staging after induction chemotherapy.

  • Pancreatic cancer: no survival benefit for early vs later adjuvant chemotherapy

    Meta-analysis shows survival benefit for early ACT in colorectal and gastric cancer.

  • Nonfunctional pancreatic neuroendocrine tumors: how many lymph nodes for staging?

    The study is the first to determine the procedure-specific LN number needed to accurately stage PanNETs.

  • Pancreatic cancer: better survival with proton-beam chemoradiotherapy

    Proton beams allow targeted delivery of higher doses with less collateral damage.

  • AACR 2019—Rucaparib maintenance shows benefit in pancreatic cancer

    Interim analysis of 19 patients with BRCA1/2 or PALB2 mutations.

  • Pancreatic cancer: MR-guided radiotherapy boosts survival

    Offers dose escalation without increased risk for acute toxicity.

  • Serious thromboembolic events reported in patients receiving Onivyde

    Advise patients to seek medical advice immediately if signs or symptoms of thromboembolism occur.

  • ESMO updates guidelines for pancreatic cancer

    Incorporates new data for mFOLFIRINOX and adjuvant gemcitabine-capecitabine.

  • ESMO updates pancreatic cancer guideline
    ESMO updates pancreatic cancer guideline

    mFOLFIRINOX is now recommended as first adjuvant chemotherapy after resection of pancreatic cancer in fit patients.

  • Pancreatic cancer: neoadjuvant GnP tied to higher R0 resection rate

    Gemcitabine plus nab-paclitaxel shows benefit in borderline resectable disease.

  • GI cancer: time to do more in tackling unintentional weight loss?

    Interventions needed to increase awareness.

  • Load more